Drug-induced ocular disorders

Drug Safety

Volumn 31, Issue 2, 2008, Pages 127-141

  Li, Junping ^a,b   Tripathi, Ramesh C ^c   Tripathi, Brenda J ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^c UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Adrenergic receptor agonists, adverse reactions; Adrenergic receptor antagonists, adverse reactions; Amiodarone, adverse reactions; Antineoplastics, adverse reactions; Cholinergic receptor antagonists, adverse reactions; Corticosteroids, adverse reactions

Indexed keywords

ADRENALIN; ALLOPURINOL; AMIODARONE; AMPICILLIN; BOTULINUM TOXIN A; BUSULFAN; CAPTOPRIL; CEFAZOLIN; CHLOROQUINE; CHLORPROMAZINE; CLINDAMYCIN; DOCETAXEL; DOXYCYCLINE; ETHAMBUTOL; IPRATROPIUM BROMIDE; ISONIAZID; ISOTRETINOIN; LINEZOLID; PACLITAXEL; PARACETAMOL; PENICILLIN G; PHENOBARBITAL; SILDENAFIL; SULFADIAZINE; TAMOXIFEN; TAMSULOSIN; TOPIRAMATE; TRIAMCINOLONE; VANCOMYCIN;

BLEPHAROSPASM; BLINKING; BLURRED VISION; CATARACT; CATARACT EXTRACTION; CLINICAL FEATURE; CLOSED ANGLE GLAUCOMA; COLOR VISION; CONJUNCTIVITIS; CORNEA INJURY; CORNEA ULCER; DARK ADAPTATION; DIFFERENTIAL DIAGNOSIS; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRY EYE; ERYTHEMA MULTIFORME; EYE DISEASE; EYELID DISEASE; HUMAN; INTRAOPERATIVE FLOPPY IRIS SYNDROME; ISCHEMIC OPTIC NEUROPATHY; KERATOCONJUNCTIVITIS; LONG TERM CARE; NIGHT VISION; NONHUMAN; OPEN ANGLE GLAUCOMA; OPTIC NERVE DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PTOSIS; RETINA MACULOPATHY; RETINOPATHY; REVIEW; SIDE EFFECT; STEROID THERAPY; SYNDROME; UVEA DISEASE;

EID: 38549111894     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200831020-00003     Document Type: Review

References (63)

1. Tripathi RC, Tripathi BJ. The eye. In: Riddell R, editor. Pathology of drug-induced and toxic diseases. New York (NY): Churchill Livingstone, 1982: 377-456
2. Physicians' desk reference. 60th ed. Montvale (NJ): Thomson Healthcare, 2006
3. PDR® for nonprescription drugs, dietary supplements and herbs. 2nd ed. Montvale (NJ): Thomson Healthcare, 2006
4. Fraunfelder FT, Fraunfelder FW. Drug-induced ocular side effects. Boston (MA): Butterworth-Heinemann, 2001
5. Bron AJ, Tripathi RC, Tripathi BJ. Wolff's anatomy of the eye and orbit. London (UK): Chapman and Hall, 1997
6. Tripathi BJ, Tripathi RC, Kolli SP. Cytotoxicity of ophthalmic preservatives on human corneal epithelium. Lens Eye Toxic Res 1992; 9 (3-4): 361-75
7. Gould HL. Solving the preservative paradox. Ophthalmology management [online]. Available from URL: http//www.ophthalmologymanagement.com [Accessed 2007 Jan 12]
8. Dutot M, Pouzaud F, Larosche I, et al. Fluoroquinolone eye drop-induced cytotoxocity: role of preservative in P2X7 cell death receptor activation and apoptosis. Invest Ophthalmol Vis Sci 2006; 47: 2812-9
9. Lewis RA, Katz GJ, Weiss MJ, et al. Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. J Glaucoma 2007; 16 (1): 98-103
10. Lowe F. Alpha-1-adrenoceptor blockade in the treatment of benign prostatic hyperplasis. Prostate Cancer Prostatic Dis 1999; 2: 110-9
11. Thiyagarajan M. Alpha-adrenoceptor antagonists in the treatment of benign prostate hyperplasia. Pharmacology 2002; 65: 119-28
12. Nakamura S, Taniguchi T, Suzuki F, et al. Evaluation of alpha-1adrenoceptors in the rabbit iris: pharmacological characterization and expression of mRNA. Br J Pharmacol 1999; 127: 1367-74
13. Narayan P. Evans CP, Moon T. Low-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol 2003; 170: 498-502
14. Roehrborn CG, Schwinn DA. Alpha-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostate hyperplasia. J Urol 2004; 171: 1029-35
15. Chang DF, Campbell JR. Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg 2005; 31: 664-73
16. Ciccone J. ASCRS and urologists team up on Flomax [online]. Available from URL: http://www.eyeworld.org/article.php-?.sid = 3285&strict = &morphologic = &query = Ciccone%20J [Accessed 2006 Nov 14]
17. Tripathi RC, Tripathi BJ, Haggerty C. Drug-induced glaucomas. Drug Safety 2003; 26 (11): 749-67
18. Tripathi RC, Parapuram SK, Tripathi BJ, et al. Corticosteroids and glaucoma risk. Drugs Aging 1999 Dec; 15 (6): 439-50
19. Jonas JB, Kressig I, Degen R. Secondary chronic open-angle glaucoma after intravitrreal triamcinolone acetonide. Arch Ophthalmol 2003; 121: 729-30
20. Smithen LM, Ober MD, Maranan L, et al. Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol 2004; 138: 740-3
21. Fabre-Guillevin E, Tchen N, Anibali-Charpiat M-F, et al. Taxane-induced glaucoma. Lancet 1999; 354 (9185): 1181-2
22. Darkeh AK, Silverberg MA. Glaucoma, acute angle-closure [online]. Available from URL: http://www.emedicine.com/emerg/topic752.htm [Accessed 2007 Jun 8]
23. Bradford CA. Basic ophthalmology for medical students and primary care residents. 8th ed. San Francisco (CA): American Academy of Ophthalmology, 2004
24. Marsh BC, Cantor LB. The Spaeth gonioscopic grading system: assessing the configuration of the anterior chamber angle. Glaucoma Today 2005; May/Jun: 22-5
25. Rho DS. Acute angle-closure glaucoma after albuterol nebulizer treatment. Am J Ophthalmol 2000; 130 (1): 123
26. Shah P, Dhurjon L, Metcalfe T, et al. Acute angle-closure glaucoma associated with nebulised ipratropium bromide and salbutamol. BMJ 1992; 304 (6818): 40-1
27. Hall SK. Acute angle-closure glaucoma as a complication of combined beta-agonist and ipratropium bromide therapy in the emergency department. Ann Emerg Med 1994; 23 (4): 884-7
28. Dobrilla G, Felder M, Chilovi F, et al. Exacerbation of glaucoma associated with both cimetidine and ranitidine [letter]. Lancet 1982; I (8280): 1078
29. Banta JT, Hoffman K, Budenz DL, et al. Presumed topriamate-induced bilateral acute angle-closure glaucoma. Am J Ophthalmol 2001; 132 (1): 112-4
30. Rhee DJ, Goldberg MJ, Parrish RK. Bilateral angle-closure glaucoma and ciliary body swelling from topiramate. Arch Ophthalmol 2001; 119 (11): 1721-3
31. Sankar PS, Pasquale LR, Grosskreutz CL. Uveal effusion and secondary angle-closure glaucoma associated with topiramate use. Arch Ophthalmol 2001; 119: 1210-1
32. Fraunfelder FW, Fraunfelder FT, Keates EU. Topiramate-associated acute, bilateral, secondary angle-closure glaucoma. Ophthamology 2004; 111: 109-11
33. Tripathi RC, Kipp MA, Tripathi BJ, et al. Ocular toxicity of prednisone in pediatric patients with inflammatory bowel disease. Lens Eye Toxic Res 1992; 9 (3-4): 469-82
34. Jonas JB, Kreissig I, Degenring R. Intravitreal triamcinolone acetonide for the treatment of intraocular proliferative, exudative, and neovascular diseases. Prog Retin Eye Res 2005; 24 (5): 587-611
35. Jonas JB. Intravitreal triamcinolone acetonide: a change in paradigm. Ophthalmic Res 2006; 38 (4): 218-45
36. Cekic O, Chang S, Tseng JJ, et al. Cataract progression after intravitreal triamcinolone injection. Am J Ophthalmol 2005; 139: 993-8
37. Grimes P, von Sallmann L, Frichette A. Influence of Myleran on cell proliferation in the lens epithelium. Invest Ophthalmol 1964; 3: 566-76
38. Weiner A, Sandberg MA, Gaudio AR, et al. Hydroxychloroquine retinopathy. Am J Ophthalmol 1991; 112: 528-34
39. Roque MR, Roque BL, Foster S. Chloroquine/hydroxycholoroquine toxicity [online]. Available from URL: http://www.emedicine.com/oph/topic245.htm [Accessed 2006 Nov 21]
40. Easterbrook M. Detection and prevention of maculopathy associated with antimalarials. Int Ophthalmol Clinic 1999; 39 (2): 49-57
41. Bernstein HN. Chloroquine ocular toxicity. Surv Ophthalmol 1967; 12 (5): 415-47
42. Bernstein HN. Ocular safety of hydroxychloroquine. Ann Ophthalmol 1991; 23 (8): 292-6
43. Levy GD, Munz SJ, Paschal J. Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice. Arthritis Rheum 1997; 40 (8): 1482-6
44. Simmons ST. 2007-2008 BCSC Section10: glaucoma. San Francisco (CA): American Academy of Ophthalmology, 2007
45. Marmor MF, Carr RE, Esterbrook M, et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy [online]. Available from URL: http://www.aao.org/education/statements/upload/Recommendations-on-Screening-for- Chloroquine-and-Hydroxychlorquine-Retinopathy.pdf [Accessed 2007 Jun 8]
46. The University of Michigan Kellogg Eye Center [online]. Available from URL: http://www.kellogg.umich.edu/vtm/retina_cases/48/history.html [Accessed 2007 Feb 2]
47. Tekell JL, Silva JA, Maas JA, et al. Thioridazine-induced retinopathy. Am J Psychiatry 1996; 153 (9): 1234-5
48. Shah GK, Auerbach DB, Augsburger JJ, et al. Acute thioridazine retinopathy. Arch Ophthalmol 1998; 116 (6): 826-7
49. Gorin MB, Day R, Costantino JP, et al. Long-term tamoxifen citrate use and potential ocular toxicity. Am J Ophthalmol 1998; 125: 493-50
50. Gianni L, Panzini I, Li S, et al. Ocular toxicity during adjunct chemoendocrine therapy for early breast cancer: results from international breast cancer study group trials. Cancer 2006; 106: 505-13
51. Weleber RG, Denman ST, Hanifin JM, et al. Abnormal retinal function associated with isotretinoin therapy fro acne. Arch Ophthalmol 1986; 104: 831-7
52. Rucker JC, Hamilton SR, Bardenstein D, et al. Linezolid-associated toxic optic neuropathy. Neurology 2006; 66: 595-8
53. Macaluso DC, Shults WT, Fraunfelder FT. Features of amiodarone-induced optic neuropathy. Am J Ophthalmol 1999; 127: 610-2
54. Marmor MF. Sildenafil (Viagra) and ophthalmology. Arch Ophthalmol 1999; 117: 518-9
55. Fraunfelder FW. Visual effects associated with erectile dysfunction agents. Am J Ophthalmol 2005; 140 (4): 723-4
56. Pomeranz HD, Smith KH, Hart WM, et al. Sildenafil-associated nonarteritic anterior ischemic optic neuropathy. Ophthalmology 2003; 110 (9): 1860-1
57. Fraunfelder FW, Fraunfelder FT. Drug-related adverse effects of clinical importance to the ophthalmologists [online]. Available from URL: http://piodr.sterling.net/index.cfm?.fuseaction= home.whatsnew [Accessed 2007 Jun 8]
58. Leibold JE. The ocular toxicity of ethambutol and its relation to dose. Ann NY Acad Sci 1966; 135: 904-9
59. Chatterjee VKK, Buchanan DR, Friedmann AI, et al. Ocular toxicity following ethambutol in standard dosage. Br J Dis Chest 1986; 80: 288-90
60. Smith JL. Should ethambutol be barred? J Clin Neuroopthalmol 1987; 7: 84-6
61. Barron GJ, Tepper L, Lovine G. Ocular toxicity from ethambutol. Am J Ophthalmol 1974; 77: 256-60
62. Citron KM, Thomas GO. Ocular toxicity from ethambutol. Thorax 1986; 41: 737-9
63. Kozak SF, Inderlied CB, Hsu HY, et al. The role of copper on thambutol's antimicrobial action and implication for ethambutol-induced optic neuropathy. Diagn Microbiol Infect Dis 1998; 30 (2): 83-7